245 related articles for article (PubMed ID: 32920733)
21. Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer.
Li X; Abramson RG; Arlinghaus LR; Kang H; Chakravarthy AB; Abramson VG; Farley J; Mayer IA; Kelley MC; Meszoely IM; Means-Powell J; Grau AM; Sanders M; Yankeelov TE
Invest Radiol; 2015 Apr; 50(4):195-204. PubMed ID: 25360603
[TBL] [Abstract][Full Text] [Related]
22. Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy.
Drisis S; Metens T; Ignatiadis M; Stathopoulos K; Chao SL; Lemort M
Eur Radiol; 2016 May; 26(5):1474-84. PubMed ID: 26310583
[TBL] [Abstract][Full Text] [Related]
23. Assessment of Early Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer Using Amide Proton Transfer-weighted Chemical Exchange Saturation Transfer MRI: A Pilot Study.
Zhang S; Rauch GM; Adrada BE; Boge M; Mohamed RMM; Abdelhafez AH; Son JB; Sun J; Elshafeey NA; White JB; Musall BC; Miyoshi M; Wang X; Kotrotsou A; Wei P; Hwang KP; Ma J; Pagel MD
Radiol Imaging Cancer; 2021 Sep; 3(5):e200155. PubMed ID: 34477453
[TBL] [Abstract][Full Text] [Related]
24. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.
Braman NM; Etesami M; Prasanna P; Dubchuk C; Gilmore H; Tiwari P; Plecha D; Madabhushi A
Breast Cancer Res; 2017 May; 19(1):57. PubMed ID: 28521821
[TBL] [Abstract][Full Text] [Related]
25. A Radiomics Model Based on Synthetic MRI Acquisition for Predicting Neoadjuvant Systemic Treatment Response in Triple-Negative Breast Cancer.
Hwang KP; Elshafeey NA; Kotrotsou A; Chen H; Son JB; Boge M; Mohamed RM; Abdelhafez AH; Adrada BE; Panthi B; Sun J; Musall BC; Zhang S; Candelaria RP; White JB; Ravenberg EE; Tripathy D; Yam C; Litton JK; Huo L; Thompson AM; Wei P; Yang WT; Pagel MD; Ma J; Rauch GM
Radiol Imaging Cancer; 2023 Jul; 5(4):e230009. PubMed ID: 37505106
[TBL] [Abstract][Full Text] [Related]
26. Diffusion-Weighted Imaging With Apparent Diffusion Coefficient Mapping for Breast Cancer Detection as a Stand-Alone Parameter: Comparison With Dynamic Contrast-Enhanced and Multiparametric Magnetic Resonance Imaging.
Pinker K; Moy L; Sutton EJ; Mann RM; Weber M; Thakur SB; Jochelson MS; Bago-Horvath Z; Morris EA; Baltzer PA; Helbich TH
Invest Radiol; 2018 Oct; 53(10):587-595. PubMed ID: 29620604
[TBL] [Abstract][Full Text] [Related]
27. Assessment of Response to Neoadjuvant Systemic Treatment in Triple-Negative Breast Cancer Using Functional Tumor Volumes from Longitudinal Dynamic Contrast-Enhanced MRI.
Panthi B; Adrada BE; Candelaria RP; Guirguis MS; Yam C; Boge M; Chen H; Hunt KK; Huo L; Hwang KP; Korkut A; Lane DL; Le-Petross HC; Leung JWT; Litton JK; Mohamed RM; Musall BC; Pashapoor S; Patel MM; Perez F; Son JB; Thompson A; Valero V; Wei P; White J; Xu Z; Pinsky L; Tripathy D; Yang W; Ma J; Rauch GM
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831368
[TBL] [Abstract][Full Text] [Related]
28. A multiparametric approach to predict triple-negative breast cancer including parameters derived from ultrafast dynamic contrast-enhanced MRI.
Ohashi A; Kataoka M; Iima M; Honda M; Ota R; Urushibata Y; Dominik Nickel M; Toi M; Zackrisson S; Nakamoto Y
Eur Radiol; 2023 Nov; 33(11):8132-8141. PubMed ID: 37286791
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of pathological complete response after neoadjuvant systemic treatment of invasive breast cancer using diffusion-weighted imaging compared with dynamic contrast-enhanced based kinetic analysis.
Ota R; Kataoka M; Iima M; Honda M; Ohashi A; Ohno Kishimoto A; Miyake KK; Yamada Y; Takeuchi Y; Toi M; Nakamoto Y
Eur J Radiol; 2022 Sep; 154():110372. PubMed ID: 35667297
[TBL] [Abstract][Full Text] [Related]
30. Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy.
Hahn SY; Ko EY; Han BK; Shin JH; Ko ES
Eur J Radiol; 2014 Feb; 83(2):283-8. PubMed ID: 24315957
[TBL] [Abstract][Full Text] [Related]
31. Characterization of breast cancer subtypes based on quantitative assessment of intratumoral heterogeneity using dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging.
Kim JJ; Kim JY; Suh HB; Hwangbo L; Lee NK; Kim S; Lee JW; Choo KS; Nam KJ; Kang T; Park H
Eur Radiol; 2022 Feb; 32(2):822-833. PubMed ID: 34345946
[TBL] [Abstract][Full Text] [Related]
32. Quantitative evaluation of breast cancer response to neoadjuvant chemotherapy by diffusion tensor imaging: Initial results.
Furman-Haran E; Nissan N; Ricart-Selma V; Martinez-Rubio C; Degani H; Camps-Herrero J
J Magn Reson Imaging; 2018 Apr; 47(4):1080-1090. PubMed ID: 28901594
[TBL] [Abstract][Full Text] [Related]
33. Radiomics Analysis Based on Automatic Image Segmentation of DCE-MRI for Predicting Triple-Negative and Nontriple-Negative Breast Cancer.
Ma M; Gan L; Jiang Y; Qin N; Li C; Zhang Y; Wang X
Comput Math Methods Med; 2021; 2021():2140465. PubMed ID: 34422088
[TBL] [Abstract][Full Text] [Related]
34. Triple-negative breast cancer on contrast-enhanced MRI and synthetic MRI: A comparison with non-triple-negative breast carcinoma.
Matsuda M; Tsuda T; Ebihara R; Toshimori W; Okada K; Takeda S; Okumura A; Shiraishi Y; Suekuni H; Kamei Y; Kurata M; Kitazawa R; Mochizuki T; Kido T
Eur J Radiol; 2021 Sep; 142():109838. PubMed ID: 34217136
[TBL] [Abstract][Full Text] [Related]
35. Ultrafast dynamic contrast-enhanced breast MRI: association with pathologic complete response in neoadjuvant treatment of breast cancer.
Kim JH; Park VY; Shin HJ; Kim MJ; Yoon JH
Eur Radiol; 2022 Jul; 32(7):4823-4833. PubMed ID: 35064805
[TBL] [Abstract][Full Text] [Related]
36. Diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping as a quantitative imaging biomarker for prediction of immunohistochemical receptor status, proliferation rate, and molecular subtypes of breast cancer.
Horvat JV; Bernard-Davila B; Helbich TH; Zhang M; Morris EA; Thakur SB; Ochoa-Albiztegui RE; Leithner D; Marino MA; Baltzer PA; Clauser P; Kapetas P; Bago-Horvath Z; Pinker K
J Magn Reson Imaging; 2019 Sep; 50(3):836-846. PubMed ID: 30811717
[TBL] [Abstract][Full Text] [Related]
37. MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
Choudhery S; Gomez-Cardona D; Favazza CP; Hoskin TL; Haddad TC; Goetz MP; Boughey JC
Acad Radiol; 2022 Jan; 29 Suppl 1(Suppl 1):S145-S154. PubMed ID: 33160859
[TBL] [Abstract][Full Text] [Related]
38. Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer.
Panthi B; Mohamed RM; Adrada BE; Boge M; Candelaria RP; Chen H; Hunt KK; Huo L; Hwang KP; Korkut A; Lane DL; Le-Petross HC; Leung JWT; Litton JK; Pashapoor S; Perez F; Son JB; Sun J; Thompson A; Tripathy D; Valero V; Wei P; White J; Xu Z; Yang W; Zhou Z; Yam C; Rauch GM; Ma J
Front Oncol; 2023; 13():1264259. PubMed ID: 37941561
[TBL] [Abstract][Full Text] [Related]
39. Identification of triple-negative breast cancer and androgen receptor expression based on histogram and texture analysis of dynamic contrast-enhanced MRI.
Xu WJ; Zheng BJ; Lu J; Liu SY; Li HL
BMC Med Imaging; 2023 Jun; 23(1):70. PubMed ID: 37264313
[TBL] [Abstract][Full Text] [Related]
40. Test-Retest Performance of a 1-Hour Multiparametric MR Image Acquisition Pipeline With Orthotopic Triple-Negative Breast Cancer Patient-Derived Tumor Xenografts.
Ge X; Quirk JD; Engelbach JA; Bretthorst GL; Li S; Shoghi KI; Garbow JR; Ackerman JJH
Tomography; 2019 Sep; 5(3):320-331. PubMed ID: 31572793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
